Skip to content

Available 24/7 for Urgent On-Site or Virtual Consulting

  • (208) 971-6430
  • [email protected]

FDA Inspections

Consulting and Compliance
  • Industries
    • Biologics
    • Cosmetics
    • Dietary Supplements
    • Medical Devices
    • Pet Food and Animal Health
    • Pharmaceuticals
  • Services
    • FDA 483 Response Consulting
    • FDA Inspection Facilitation Services
    • FDA Inspection Readiness Services
    • FDA Inspection Training
    • FDA Warning Letter Remediation
    • Mock FDA Inspections and Gap Assessment Services
    • Virtual FDA Inspection Consulting
  • Resources
  • News
  • Industries
    • Biologics
    • Cosmetics
    • Dietary Supplements
    • Medical Devices
    • Pet Food and Animal Health
    • Pharmaceuticals
  • Services
    • FDA 483 Response Consulting
    • FDA Inspection Facilitation Services
    • FDA Inspection Readiness Services
    • FDA Inspection Training
    • FDA Warning Letter Remediation
    • Mock FDA Inspections and Gap Assessment Services
    • Virtual FDA Inspection Consulting
  • Resources
  • News
Contact Us
  • Female scientist in a white lab coat and safety glasses examining a vial in a biologics laboratory.
    Inspections

    Pre-Approval Inspection Readiness for Biologics Manufacturers

    ByFDA Inspections Team September 25, 2025September 25, 2025

    Navigating a pre-approval inspection for biologics is the final, critical hurdle before commercialization. This pivotal assessment by the FDA determines if your manufacturing processes, facilities, and quality systems can consistently produce a safe and effective product. This guide offers an in-depth roadmap for 2025, focusing on the unique complexities of biologics. We cover everything from establishing a bulletproof Quality Management System (QMS) and ensuring data integrity to preparing your facility and team for intense regulatory scrutiny. Learn the key strategies to demonstrate control, avoid common pitfalls, and confidently prove your readiness for market approval.

    Read More Pre-Approval Inspection Readiness for Biologics ManufacturersContinue

  • A female FDA inspector in a lab coat, mask, and hairnet reviews a cosmetic product label while holding a clipboard in a modern facility, symbolizing the 2025 FDA cosmetic labeling requirements and compliance checks.
    Inspections

    FDA Cosmetic Labeling Requirements for 2025: What’s Changed?

    ByFDA Inspections Team September 25, 2025September 25, 2025

    Navigating the new cosmetic labeling FDA requirements for 2025 is critical for market success and avoiding regulatory action. With the full implementation of the Modernization of Cosmetics Regulation Act (MoCRA), companies face significant changes in how they declare allergens, list contact information, and ensure label transparency. This comprehensive guide breaks down the essential updates, providing actionable insights to help you align your product labels with the latest standards to remain compliant and competitive.

    Read More FDA Cosmetic Labeling Requirements for 2025: What’s Changed?Continue

  • A male professional in a white lab coat reviews a medical device GxP audit checklist while working on a laptop in a modern office, highlighting preparation, compliance, and inspection readiness for 2025.
    Inspections

    Medical Device GxP Audit Checklist for 2025: Are You Inspection-Ready?

    ByFDA Inspections Team September 25, 2025September 25, 2025

    In the highly regulated medical device industry, GxP compliance is not just a best practice—it is a fundamental requirement for market access and patient safety. With regulatory scrutiny intensifying in 2025, a proactive approach to quality is essential. This article provides a comprehensive medical device GxP audit checklist designed to help manufacturers prepare for FDA inspections and other regulatory assessments. From your Quality Management System to CAPA procedures and post-market surveillance, we cover every critical area.

    Read More Medical Device GxP Audit Checklist for 2025: Are You Inspection-Ready?Continue

  • An FDA inspector in a white lab coat, mask, and hairnet examines a cosmetic bottle inside a clean production facility, holding a clipboard to record observations during a compliance audit for cosmetic manufacturers.
    Inspections

    FDA Audits for Cosmetic Manufacturers: Compliance Essentials You Can’t Ignore

    ByFDA Inspections Team September 25, 2025September 25, 2025

    Are you prepared for FDA audits for cosmetic manufacturers? With the new MoCRA regulations, the FDA has enhanced authority to inspect facilities and enforce compliance. This guide covers the essentials you can’t ignore, from understanding GMP requirements and maintaining meticulous records to handling adverse event reporting. Learn how to prepare for an inspection, respond to observations, and build a culture of quality that protects your brand and consumers. Stay ahead of regulatory changes and avoid costly penalties.

    Read More FDA Audits for Cosmetic Manufacturers: Compliance Essentials You Can’t IgnoreContinue

  • Close-up of a person in a white lab coat reviewing a GDP compliance checklist for biologics logistics. The clipboard shows several checked boxes, with vials, ampoules, a laptop, and a notebook neatly arranged on a wooden desk, symbolizing quality control.
    Inspections

    GDP Compliance in Biologics Logistics: A Complete Guide for 2025

    ByFDA Inspections Team September 25, 2025September 25, 2025

    Discover the essentials of Good Distribution Practice (GDP) for the biologics supply chain in our comprehensive 2025 guide. This article explores the critical challenges of maintaining GDP compliance in biologics logistics, from stringent temperature control and real-time monitoring to robust data integrity and secure transportation. Learn how to navigate regulatory expectations, validate your processes, and implement a resilient Quality Management System (QMS) to prevent costly compliance failures and ensure product safety.

    Read More GDP Compliance in Biologics Logistics: A Complete Guide for 2025Continue

  • A professional in a white lab coat prepares for a virtual FDA inspection, focused on his laptop while taking notes on a clipboard at a wooden desk in a clean office environment with shelves and a wall clock.
    Inspections

    Preparing for a Virtual FDA Inspection: A Step-by-Step Industry Guide

    ByFDA Inspections Team September 25, 2025September 25, 2025

    The rise of remote work has transformed regulatory oversight, making virtual FDA inspections a new standard. Preparing for a virtual FDA inspection requires a proactive strategy that addresses technology, documentation, and team readiness. This guide provides a detailed roadmap for manufacturers to navigate this digital-first approach. We cover everything from setting up secure data-sharing platforms to training your staff for live-streamed facility tours and remote interviews, ensuring you can confidently demonstrate compliance.

    Read More Preparing for a Virtual FDA Inspection: A Step-by-Step Industry GuideContinue

  • A male scientist in protective gear participates in a remote FDA inspection via video call with a female inspector on his computer screen, symbolizing the shift to virtual regulatory practices during and after COVID-19.
    Inspections

    How COVID Changed Remote FDA Inspections—and What It Means for 2025

    ByFDA Inspections Team September 25, 2025September 25, 2025

    The COVID-19 pandemic acted as a catalyst, forcing the FDA to rapidly adapt its traditional on-site inspection methods. This shift gave rise to Remote Interactive Evaluations (RIEs) and other virtual oversight tools, fundamentally altering the regulatory landscape. This article explores the lasting remote FDA inspections COVID impact, detailing the transition from physical to virtual audits, the key technologies involved, and the new compliance challenges companies face as we head into 2025.

    Read More How COVID Changed Remote FDA Inspections—and What It Means for 2025Continue

  • Person holding an FDA warning letter while preparing a written response at a wooden desk. A laptop, notebook, pen, and a document labeled “RESPONSE” are neatly arranged, symbolizing strategy and timely communication.
    Warning Letters

    How to Respond to an FDA Warning Letter: Strategy, Timing & Tone

    ByFDA Inspections Team September 25, 2025September 25, 2025

    Receiving an FDA warning letter is a critical event for any regulated company. It signals significant regulatory violations that require immediate and thorough attention. A poorly crafted response can escalate the situation, leading to severe penalties. This guide provides a comprehensive strategy on how to respond to an FDA warning letter, covering everything from the initial assessment and team assembly to the critical 15-day deadline, drafting a detailed response, and implementing effective corrective actions.

    Read More How to Respond to an FDA Warning Letter: Strategy, Timing & ToneContinue

  • A male professional in a white lab coat reviews an FDA inspection readiness plan on a clipboard in a modern office. Sitting at a wooden desk with a laptop, he writes notes carefully, representing preparation, compliance, and focus on regulatory standards.
    Inspections

    Building an FDA Inspection Readiness Plan: Steps for a Compliant Facility

    ByFDA Inspections Team September 25, 2025September 25, 2025

    Prepare your facility for scrutiny with a comprehensive FDA inspection readiness plan. This guide outlines the essential steps, from assembling a dedicated readiness team and conducting rigorous mock inspections to mastering document control and training your staff. Learn how to proactively identify and address potential compliance gaps, manage logistics for the inspection day, and handle post-inspection communications effectively. A solid plan minimizes stress and prevents costly regulatory actions.

    Read More Building an FDA Inspection Readiness Plan: Steps for a Compliant FacilityContinue

  • Close-up of a person holding a printed "Part 11 Software Validation Checklist" while sitting at a wooden desk. The person holds a pen, ready to check off items. A laptop, spiral notebook, calculator, and documents are arranged neatly, symbolizing compliance planning.
    Inspections

    Part 11 Software Validation Checklist: Ensure Compliance from Day One

    ByFDA Inspections Team September 25, 2025September 25, 2025

    In the life sciences industry, data integrity is paramount. FDA’s 21 CFR Part 11 sets the standard for electronic records and signatures, making software validation a non-negotiable activity. Failing to comply can lead to significant regulatory actions, including Form 483s and Warning Letters. This guide provides a comprehensive part 11 software validation checklist to help you navigate the complexities of compliance, ensuring your systems are secure, reliable, and inspection-ready from day one.

    Read More Part 11 Software Validation Checklist: Ensure Compliance from Day OneContinue

Page navigation

Previous PagePrevious 1 … 9 10 11 12 13 Next PageNext

FDA Inspections

Your trusted partner for FDA compliance and inspection readiness. With former ex-FDA’ers  on our team, we provide the expertise and confidence you need to succeed.

  • (208) 971-6430
  • [email protected]

Services

  • Pre-Inspection Prep
  • On-Site Support
  • CAPA Development
  • Staff Training
  • Documentation
  • Emergency Support

Industries

  • Pharmaceuticals
  • Medical Devices
  • Biotechnology
  • Food & Beverage
  • Cosmetics
  • Clinical Research
© 2024 FDA Inspections. All rights reserved.
  • Privacy Policy
  • Terms of Service
  • Disclaimer
THE IMMERSIVE FDA INSPECTION EXPERIENCE →
WARNING LETTERS 483 OBSERVATIONS